GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipum AB (OSTO:LIPUM) » Definitions » Land And Improvements

Lipum AB (OSTO:LIPUM) Land And Improvements : kr0.00 Mil (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Lipum AB Land And Improvements?

Lipum AB's land and improvements for the quarter that ended in Mar. 2025 was kr0.00 Mil.


Lipum AB Land And Improvements Historical Data

The historical data trend for Lipum AB's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipum AB Land And Improvements Chart

Lipum AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Land And Improvements
Get a 7-Day Free Trial - - - - -

Lipum AB Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Land And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Lipum AB Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.


Lipum AB Business Description

Traded in Other Exchanges
N/A
Address
Tvistevagen 48 C, Umea, SWE, 907 36
Lipum AB is a clinical-stage biopharmaceutical company specializing in the discovery and development of a novel treatment for chronic inflammatory diseases. The candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule (BSSL) of the immune system. The development is supported by solid pre-clinical data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need.

Lipum AB Headlines

No Headlines